High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia.

ABSTRACT:

Background

Acute myeloid leukemia (AML) pertains to a hematologic malignancy with heterogeneous therapeutic responses. Improvements in risk stratification in AML patients are warranted. MicroRNAs have been associated with the pathogenesis of AML.

Methods

To examine the prognostic value of miR-25, 162 cases with de novo AML were classified into two groups according to different treatment regimens.

Results

In the chemotherapy group, cases with upregulated miR-25 expression showed relatively longer overall survival (OS; P = 0.0086) and event-free survival (EFS; P = 0.019). Multivariable analyses revealed that miR-25 upregulation is an independent predictor for extended OS (HR = 0.556, P = 0.015) and EFS (HR = 0.598, P = 0.03). In addition, all

SUBMITTER: Niu M 

PROVIDER: S-EPMC6505210 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature